

# Antibe Therapeutics Inc

09:35 28 Aug 2019

## Antibe Therapeutics sees fiscal first quarter revenue rise thanks to higher sales in the United States

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) has reported fiscal first quarter results showing an increase in revenue thanks to higher sales in the United States.

For the three months ended June 30, 2019, the biotech company said its revenue from product sales increased to C\$2.763 million, up from C\$2.543 million a year earlier.

### READ: Antibe Therapeutics: Phase 2B study of flagship drug ATB-346 to treat osteoarthritis pain 'proceeding well'

The firm noted that the higher sales in the US were due to the company's focused marketing in the country.

It reported a gross profit of C\$1.037 million in the period, up from C\$984,000 a year earlier, although its net loss increased to C\$3.285 million from C\$2.663 million in 2018, while its basic and diluted loss per share held steady at C\$0.01.

Expenses for the three month period rose to C\$4.213 million, compared to C\$3.479 million for the three months ended June 30, 2018, reflecting an increase in general and administrative, selling and marketing, research and development, stock-based compensation and amortization and depreciation expenses.

At the end of June, Antibe had cash on its books of C\$3.963 million, down from C\$5.993 million as at March 31, 2019.

Overall, the company said its expects net losses to continue as its flagship ATB-346 drug, used to treat acute and chronic pain associated with osteoarthritis, advances through the regulated clinical phases of its development program.

On Tuesday, Antibe provided an update on the Phase 2B study of ATB-346, which commenced in March 2019 and is designed to validate the effectiveness of the drug in reducing pain and establish the dose for Phase 3 development.


In its statement, the group said; "The clinical trial is proceeding well and the company is pleased with the execution and quality of patient screening, which determines admittance into the study across the 35 clinical sites."

Contact the author at [jon.hopkins@proactiveinvestors.com](mailto:jon.hopkins@proactiveinvestors.com)

**Price:** 0.34

**Market Cap:** \$131.06 m

#### 1 Year Share Price Graph



October 2019 April 2020 October 2020

#### Share Information

**Code:** ATE

**Listing:** TSX-V

<b>52 week</b>	<b>High</b>	<b>Low</b>
	0.89	0.305

**Sector:** Pharma & Biotech

**Website:** [antibethera.com](http://antibethera.com)

#### Company Synopsis:

*Antibe Therapeutics is a publicly-traded biotechnology company pursuing a breakthrough advance in the treatment and prevention of inflammation. Antibe's drug pipeline addresses a \$20+ billion market in non-addictive pain management, cardiovascular disease, and cancer prevention.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).